Skip to main content

Table 5 The results of WB, IF, IHC (\( \overline{\mathrm{x}} \) ± SD)

From: RETRACTED ARTICLE: The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer

 

Control group

Group-1

Group-2

Group-3

WB (relative gray value)

Bax

0.08 ± 0.02

0.18 ± 0.12**

0.17 ± 0.17**

0.17 ± 0.02**

bcl-2

0.17 ± 0.02

0.07 ± 0.01**

0.09 ± 0.01**

0.09 ± 0.01**

CD31

0.75 ± 0.04

0.16 ± 0.02**

0.16 ± 0.04**

0.2 ± 0.01**

p-VEGFR-2

0.26 ± 0.02

0.16 ± 0.03**

0.18 ± 0.01**

0.19 ± 0.01**

MMP-2

0.71 ± 0.02

0.29 ± 0.03**

0.3 ± 0.02**

0.29 ± 0.01**

IF (positive rate%)

Bax

3.37% ± 0.91

20.97 ± 2.09**

19.13 ± 2.78**

19.73 ± 1.52**

bcl-2

17.17 ± 1.69

3.23 ± 1.35**

2.43 ± 0.79**

2.57 ± 0.5**

CD31

24.1 ± 1.15

6.73 ± 1.47**

9.53 ± 1.6**

9.7 ± 1.96**

p-VEGFR-2

16.77 ± 1.03

3.0 ± 0.29**

3.83 ± 0.61**

4.07 ± 1.04**

MMP-2

13.2 ± 1.53

2.77 ± 0.54**

2.87 ± 0.49**

2.93 ± 0.69**

IHC (positive rate%)

Bax

13.2% ± 1.07

34.17 ± 1.11**

32.83 ± 0.95**

32.77 ± 1.16**

bcl-2

31.73 ± 1.67

13.33 ± 1.59**

14.63 ± 1.48**

13.87 ± 1.89**

CD31

36.1 ± 1.69

11.63 ± 1.2**

12.67 ± 1.52**

12.33 ± 2.24**

p-VEGFR-2

35.47 ± 2.93

17.1 ± 1.31**

17.53 ± 1.6**8

18.23 ± 1.25**

MMP-2

34.9 ± 2.38

14.53 ± 1.17**

15.27 ± 0.74**

15.57 ± 2.75**

  1. Note: ** P < 0.01, medication group vs control group